OMA Guidelines Bundle

Obesity Pharmacotherapy Supplements 2026

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1544296

Contents of this Issue

Navigation

Page 4 of 19

5 Medication Classes Associated With Weight Gain Several classes of medications are associated with weight gain (see pages 10–11) • Hormones: Glucocorticoids, growth hormone, insulin • ß-Blockers: Atenolol, metoprolol, propranolol • Antidiabetic agents   ▶ Thiazolidinediones: Pioglitazone, rosiglitazone   ▶ Sulfonylureas: Glipizide, glimepiride, glyburide   ▶ Meglitinides: Repaglinide, nateglinide   ▶ Insulin • Anticonvulsants: Gabapentin, pregabalin, divalproex, carbamazepine • Atypical antipsychotics: Olanzapine, quetiapine • Antidepressants:   ▶ Tricyclic antidepressants (TCAs): Amitriptyline, imipramine   ▶ Monoamine oxidase inhibitors (MAOIs): Phenelzine   ▶ Selective serotonin reuptake inhibitors (SSRIs): Paroxetine   ▶ Atypical antidepressant: Mirtazapine • Histamine-1 receptor antagonists: Diphenhydramine, chlorpheniramine, cyproheptadine Weight-Neutral Medication Classes • Dipeptidyl peptidase-4 (DPP-4 ) inhibitors: Sitagliptin, saxagliptin, • linagliptin • Centrally acting dopamine agonist: Bromocriptine • α-Glucosidase inhibitors: Acarbose, miglitol, voglibose • Bile acid sequestrant: Colesevelam • ß-Blockers: Carvedilol, labetalol, nebivolol

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy Supplements 2026